10-Q: BioLargo Q3 2025: Revenue Plummets Amid Pooph Litigation

BioLargo reports a substantial 75% revenue decline in Q3 2025 and a $3.8 million credit loss due to a customer default, raising significant going concern doubts.

Summary

• Total revenue for the three months ended September 30, 2025, decreased by 75% to $1,103,000 from $4,351,000 in the same period of 2024.
• Total revenue for the nine months ended September 30, 2025, decreased by 49% to $7,148,000 from $14,122,000 in the same period of 2024.
• The company recorded a net loss of $7,244,000 for the three months and $11,047,000 for the nine months ended September 30, 2025, compared to losses of $1,060,000 and $2,615,000, respectively, in the prior year.
• A significant credit loss expense of $3,849,000 was recognized for the nine months ended September 30, 2025, due to a customer's (Pooph Inc.) contractual defaults, which is now subject to litigation.
• Net cash used in operating activities for the nine months ended September 30, 2025, was $6,707,000, a substantial increase from $1,290,000 in the prior year.
• The company's management has raised substantial doubt about its ability to continue as a going concern without increased revenues, cash from operations, or further financing activities.
• As of September 30, 2025, cash and cash equivalents stood at $4,546,000, up from $3,548,000 at December 31, 2024, primarily due to financing activities.
• Working capital as of September 30, 2025, was $2,324,000.

Sentiment

Score: 2

Explanation: The sentiment is highly negative due to a massive 75% revenue decline in the quarter, a significant $3.8 million credit loss from a key customer, a substantial increase in net loss, and an explicit 'going concern' warning from management. While there are ongoing development efforts and some financing, the overall financial health and immediate outlook are severely challenged.

Positives

• Cash and cash equivalents increased to $4,546,000 as of September 30, 2025, from $3,548,000 at December 31, 2024, primarily due to successful financing activities.
• Net cash provided by financing activities significantly increased to $7,269,000 for the nine months ended September 30, 2025, compared to $2,846,000 in the same period of 2024.
• Clyra Medical Technologies successfully raised $2,145,000 from sales of Series B Preferred Stock and $1,894,000 from a Warrant Holder Unit Offering during the nine months ended September 30, 2025.
• BioLargo Energy Technologies, Inc. (BETI) continues to develop its Cellinity battery technology, which has shown exceptional performance claims confirmed by a third party, including increased safety, unlimited charge/discharge cycles, and long life expectancy.
• The Aqueous Electrostatic Concentrator (AEC) for PFAS remediation has been successfully validated, demonstrated over 10,000 hours of continuous operation, and is ready for delivery and installation for a key municipal project in New Jersey.
• BioLargo Engineering, Science & Technologies, LLC (BLEST) continues to generate revenue from third-party clients, including ongoing contracts at U.S. Air Force bases for air quality control, generating approximately $100,000 per month.
• The company has secured channel partner agreements for the AEC across most of the continental United States, aiming to accelerate market adoption.
• The company has a pipeline of other cleantech innovations in various stages of development, supported by over 90 government grants.

Negatives

• Consolidated revenue for the three months ended September 30, 2025, decreased by 75% to $1,103,000, and for the nine months, it decreased by 49% to $7,148,000, primarily due to a significant decline in sales of the Pooph-branded pet odor control product.
• The company reported a substantial net loss of $11,047,000 for the nine months ended September 30, 2025, significantly worse than the $2,615,000 loss in the prior year.
• A $3,849,000 credit loss expense was recorded for the nine months ended September 30, 2025, due to the full impairment of a note and accounts receivable owed by Pooph Inc.
• Net cash used in operating activities increased significantly to $6,707,000 for the nine months ended September 30, 2025, from $1,290,000 in the same period of 2024.
• The company's management has raised substantial doubt about its ability to continue as a going concern.
• ONM Environmental, the subsidiary responsible for the Pooph product, generated an operating loss of $2,026,000 for the nine months ended September 30, 2025, compared to an operating income of $4,668,000 in the prior year.
• Clyra Medical Technologies has not yet begun commercial sales of its products and incurred total costs and expenses of $4,063,000 for the nine months ended September 30, 2025.
• BLEST generated an operating loss of $763,000 for the nine months ended September 30, 2025, reflecting its focus on internal BioLargo projects rather than external revenue generation.
• The company continues to have a material weakness in its internal controls with respect to closing its financial statements due to limited financial and personnel resources and distributed operations.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern without increasing revenues, generating cash from operations, or securing further investment capital.
• Significant customer concentration risk, as one customer (Pooph Inc.) accounted for 64% of consolidated revenue for the nine months ended September 30, 2025, and is now in litigation.
• The outcomes of the lawsuits against Pooph Inc. and the lawsuit filed by Pooph Inc. against ONM Environmental are uncertain and could materially impact future financial results.
• Inability to raise additional cash through gross profits or financing activities may lead management to curtail portions of operations.
• Long and arduous sales cycles in the water and wastewater industry, requiring extensive technical processes, feasibility studies, and regulatory approvals, pose a challenge to securing large contracts for water treatment technologies.
• Current U.S. regulatory frameworks have not yet matured to support broad adoption of advanced oxidation technologies for micropollutant removal, impacting the commercialization of the AOS.
• The company faces challenges in managing quality and timely performance, as well as access to qualified staff, to meet expanding demand for its growing list of customers and/or expected customers, particularly for PFAS and Garratt-Callahan related work.
• Material weakness in internal controls with respect to closing financial statements due to limited financial and personnel resources and lack of sophisticated reporting systems.

Future Outlook

Management does not believe gross profits for the year ending December 31, 2025, will be sufficient to fund current operations and expects to continue needing further investment capital to fund business plans and new technologies. The company plans to redeploy its pet odor control technology with new partners following the Pooph litigation, advance Cellinity battery development to larger cells and scale manufacturing, and continue the commercial rollout of the AEC PFAS treatment technology, with the New Jersey project being a key milestone. Daily development activities for the AOS water treatment system are paused, but international commercialization opportunities, particularly in Europe, are being explored.

Management Comments

• We do not believe gross profits in the year ending December 31, 2025, will be sufficient to fund our current level of operations for the remainder of the year, and therefore expect we will continue to be limited in terms of our capital resources, and therefore expect to continue to need further investment capital to fund our business plans and investments in our new technologies.
• If we are unable to raise additional cash through gross profits or financing activities, management may choose to curtail portions of our operations.
• We are focused on redeploying our technology with new partners that share our commitment to quality, transparency, and integrity, and expand the reach of our proven odor-control technology into new markets, providing consumers with safe, effective, and environmentally friendly products.
• We believe our Cellinity batteries will have features that far surpass comparable lithium-ion batteries, including increased safety, sustainable design, virtually unlimited charge/discharge cycles, and an expected useful life of up to 20 years or more.
• We are working carefully to find balance to help ensure we meet the demands of both in a practical customer centric and capital conserving way, potentially depending heavily on contact manufacturers for larger contracts as we scale up infrastructure and workforce capabilities.

Industry Context

The company operates in critical cleantech sectors addressing global challenges such as PFAS contamination, advanced water and wastewater treatment, industrial odor control, and battery energy storage. The PFAS crisis is driving demand for remediation technologies, with new EPA standards influencing market opportunities. The battery energy storage market is experiencing growing demand for safer, longer-lasting, and more eco-friendly alternatives to lithium-ion batteries, particularly for grid-scale and industrial uses like data centers. The water treatment industry is characterized by technically intensive and lengthy sales cycles, especially for municipal projects, requiring significant engineering expertise and regulatory approvals.

Comparison to Industry Standards

• CupriDyne Clean is believed to be the number-one performing industrial odor-control product in the market, offering substantial savings compared with competing products.
• The AEC PFAS remediation system is believed to have lower operating costs and generate only a fraction of PFAS-laden waste compared to common incumbent solutions like carbon filtration, ion exchange, and reverse osmosis.
• The Cellinity battery technology is expected to far surpass comparable lithium-ion batteries in terms of safety (no runaway fire risks), sustainability (no rare-earth elements, domestic supply chain), performance (unlimited charge/discharge cycles, no self-discharge), and useful life expectancy (up to 20 years or more).

Management Changes

Corporate Governance

Legal Proceedings

• On November 11, 2025, BioLargo Inc. and ONM Environmental Inc. filed a lawsuit against Pooph Inc. and Ikigai Marketing Works LLC in the United States District Court for the Central District of California (case number 8:25-cv-02516). The lawsuit alleges patent infringement, false advertising, breach of contract, false promise, unfair and fraudulent business practices, and constructive fraud. BioLargo seeks an injunction against patent infringement and false advertising, accounting for defendants' gains, compensatory damages for $1,667,292 in unpaid royalties, $2,154,110 for unpaid product, additional compensatory damages, treble/exemplary damages, and legal costs.
• Also on November 11, 2025, Pooph Inc. served ONM Environmental with a lawsuit filed in the Orange County, California Superior Court (case number 30-2025-01511009). Pooph Inc. alleges ONM Environmental breached the terms of, and the implied covenant of good faith and fair dealing of, the Preferred Master Manufacturing Agreement, seeking damages, unjust enrichment, interest, and attorneys' fees and costs, arising from ONM Environmental's refusal to fill purchase orders while Pooph Inc. was in breach of contract for failure to pay past due monies. ONM Environmental disputes these allegations and intends to vigorously defend the lawsuit.

Related Party Transactions

• Lincoln Park Capital Fund, LLC: Entered into a stock purchase agreement on December 13, 2022, allowing BioLargo to sell up to $10,000,000 of common stock. BioLargo sold 8,299,752 shares for $1,587,000 in gross proceeds during the nine months ended September 30, 2025, and an additional 2,309,974 shares for $358,000 subsequent to the quarter end.
• Pooph Inc. and Ikigai Holdings, LLC (now Ikigai Marketing Works LLC): Previously a significant customer for private-label pet odor control products, now involved in active litigation with BioLargo and ONM Environmental due to contractual defaults and alleged patent infringement.
• Vernal Bay Capital Group, LLC: Provided Clyra Medical with a $1,000,000 Revolving Line of Credit Agreement, with an outstanding balance of $134,000 as of September 30, 2025.
• Garratt-Callahan: Partnered with BioLargo engineers to develop the Aqueous Reuse Optimization System (AROS) water treatment system, with Garratt-Callahan actively marketing the system and BLEST serving as the manufacturing partner.

Stakeholder Impact

• Shareholders: Face significant dilution risk from ongoing capital raises (e.g., Lincoln Park agreement, Clyra offerings) and a substantial decrease in net loss per share. The 'going concern' warning indicates high financial risk and potential for further value erosion.
• Employees: Compensation for the CFO is solely in stock options, indicating a reliance on equity-based incentives. The need to hire more qualified staff for BLEST suggests potential growth opportunities but also operational strain.
• Customers: Customers of ONM Environmental's private-label products, particularly those previously relying on Pooph-branded products, may experience disruption. BioLargo is seeking new partners to redeploy its technology.
• Creditors: The 'going concern' warning and increased debt obligations, particularly for Clyra Medical, may raise concerns about the company's ability to meet its financial commitments.
• Suppliers/Vendors: Some vendors have received common stock or warrants in lieu of cash for services, indicating potential cash flow constraints.

Next Steps

• Redeploying pet odor control technology with new partners following the Pooph litigation to expand market reach.
• Advancing Cellinity battery development, including designing larger battery cells and establishing manufacturing processes and a supply chain for scale production.
• Exploring multiple opportunities to commercialize Cellinity batteries through joint ventures with third parties to finance manufacturing facilities.
• Executing the commercial rollout of the AEC PFAS treatment technology, with the New Jersey project representing a key milestone.
• Engaging in discussions with the US EPA for rigorous third-party pilot study validation of the AEC technology.
• Monitoring evolving regulatory trends in the U.S. and exploring international commercialization opportunities for the AOS, particularly in Europe.
• Hiring more qualified staff for BLEST to meet expanding demand for customer projects and internal BioLargo initiatives.

Key Dates

Recommendation

The filing reveals a dire financial situation with a 75% quarterly revenue decline, a massive $3.8 million credit loss from a primary customer, and a significant increase in net loss. The explicit 'going concern' warning, coupled with ongoing high-stakes litigation and a material weakness in internal controls, indicates severe operational and financial distress. While the company is pursuing new technologies and financing, the immediate risks and poor performance outweigh any potential long-term upside, making the stock a strong sell for seasoned investors.

Keywords

BioLargo, BLGO, SEC filing, 10-Q, quarterly report, financial results, net loss, revenue decline, Pooph litigation, credit loss, going concern, PFAS remediation, water treatment, battery technology, Cellinity, Clyra Medical, environmental technology, cleantech, odor control, corporate governance, capital raise